Latest Peptide News
Original reporting on the peptide industry — FDA actions and compounding decisions, supply and shortage changes, new clinical trial results, and peer-reviewed research on the peptides people actually track. Published every other day, sourced to primary documents, and written for people managing a protocol rather than for clinicians.
Browse by peptide
Peptide News
GLP-1 Muscle Loss Study Will Track DXA Scans and Grip Strength
An observational GLP-1 muscle loss study posted to ClinicalTrials.gov on September 22 will measure body composition with DXA scans plus physical function tests in adults already starting GLP-1 receptor agonist therapy. It lands alongside a new review in Maturitas that flags muscle health as one of the open questions for semaglutide in postmenopausal women.
Cagrilintide Retatrutide Combination Boosts Weight Loss in Rat Study
A team publishing in Nature Metabolism reports that a cagrilintide retatrutide combination enhanced weight loss and metabolic outcomes in obese male rats, adding rodent evidence to the idea that amylin analogues and incretin agonists work better together. The finding lands while retatrutide itself is still investigational and, separately, while antidoping chemists publish methods for detecting it in human plasma and urine.
Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance
The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.
GLP-1 After Bariatric Surgery: Phase 4 Trial Now Recruiting
Two academic randomized trials are now attacking the same unanswered question: what should happen to GLP-1 after bariatric surgery. One is recruiting 150 patients in Missouri; the other, GRABS, has just published its rationale, design and baseline characteristics. For anyone tracking a GLP-1 protocol through a planned surgery, this is the evidence that does not yet exist.
NNC0662-0419 Phase 2 Trial Compares Novo Drug to Semaglutide
A newly posted NNC0662-0419 phase 2 trial record shows Novo Nordisk testing an experimental blood-sugar medicine head-to-head against semaglutide in 270 people with type 2 diabetes. For anyone following what comes after the current generation of GLP-1 drugs, the choice of comparator is the detail worth noting.
Cagrilintide Bone Density Trial Opens With Semaglutide Comparator
A newly posted cagrilintide bone density trial puts an amylin analogue head-to-head with semaglutide and with the CagriSema combination, and its stated purpose is bone health rather than weight. For anyone tracking a GLP-1 or incretin protocol, it is a signal that skeletal outcomes are moving from footnote to primary question.
Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins
A Phase 2 tirzepatide binge eating disorder trial run by Johns Hopkins University is listed as recruiting on ClinicalTrials.gov, with 105 planned participants and a three-arm design that pits the dual incretin drug against both placebo and an established binge-eating medication. It is one of the first registered attempts to test whether an incretin therapy does anything for binge eating that is separable from weight loss.
Semaglutide Smoking Cessation Trial Opens Recruiting in Diabetes
A new semaglutide smoking cessation trial listed on ClinicalTrials.gov is recruiting 100 participants with diabetes to test the GLP-1 receptor agonist as an add-on to nicotine replacement therapy. It is one of several studies registered or published this week pushing incretin drugs well beyond weight and glucose control.
Enobosarm GLP-1 Trial: 239-Patient Muscle Study Closes Enrollment
A ClinicalTrials.gov update dated September 4, 2026 shows the enobosarm GLP-1 trial has finished enrolling 239 participants and moved into its active, non-recruiting phase. It is one of the clearest signals yet that drug development around incretin therapy has shifted from how much weight comes off to what tissue comes off with it.
Stopping and Restarting Tirzepatide Gets Its Own Clinical Trial
Registry records updated in early September 2026 show researchers are now studying stopping and restarting tirzepatide as a deliberate, measured event rather than an accident of insurance or supply. A separate Phase 3a trial is testing early semaglutide re-initiation after bariatric surgery in adolescents.
CagriSema vs Tirzepatide Trial Completes in Type 2 Diabetes
A phase 3 CagriSema vs tirzepatide trial in more than a thousand adults with type 2 diabetes has moved to completed status on the federal trial registry, setting up the first direct comparison between Novo Nordisk's investigational amylin-GLP-1 combination and Eli Lilly's approved dual agonist. Two separate phase 3 trials of cagrilintide on its own also appeared in the same registry update.
Semaglutide Lifespan Mice Study: What the Nature Paper Actually Found
A semaglutide lifespan mice study published in Nature reports that older female mice given the GLP-1 drug lived longer and scored better on health measures than untreated animals. The National Institutes of Health says the effect went beyond what calorie restriction alone produced — a claim that will shape how the drug class is discussed for years, and one that arrives the same week European regulators fined news outlets for over-enthusiastic GLP-1 coverage.